JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine ...

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Novavax shares jumped 16.6% to $7.84 in the pre-market trading session. Here are some other stocks moving in pre-market ...

Shares of Novavax NVAX surged nearly 26% in pre-market trading today after its protein-based COVID-19 vaccine, Nuvaxovid, ...

After a prolonged wait, American company Novavax (Nasdaq: NVAX) has received full approval from the US regulator for its ...

Key Takeaways The S&P 500 eked out a gain of 0.1% on Monday, May 19, 2025, as investors weighed the implications of Moody's ...

The latest investor updates on stocks that are trending on Monday.